Antonio . Lee sees the most important clinical pay-offs coming from the BRCA2 /Rad51 interaction.
In a recent article in Proceedings of the National Academy ofSciences, researchers in Lee's lab identified the portion s of BRCA2 protein that associate directly with Rad51. His strategy is 
Ne
to synthe size a small peptide that-will block this interaction. Because most breast tumors , as well as other tumors, ' have an intact BRCA2 protein, a drug that blocks this interaction might leave the tumors more susceptible to damage from radiation or drugs causing doublestranded DNA break s.
Even though the data for BRCA2 seems to be stronger, some would argue that it's difficult to imagine that BRCAI and BRCA2 are not both involved in at least some of the same pathway s. Lewis Chodosh, M.D, Ph.D., at the University of Pennsylvania Medical Center in Philadelphia, is one of those.
Finding BRCAl's Function: A More Arduous Journey
For BRCA I, the noisiest problem has been where the BRCAI protein is located in the cell. While most resear chers have found the protein in the nucleus of normal cells, some have found evidence of the protein in the cytoplasm ofmalignant cells, and one group has reported that BRCA I is present in the cell membrane and in the secretory apparatus. However, in a paper recently submitted to Nat ure Genetics, Cindy Wilson, Ph.D., from the Division of Hematology Oncology at the University of California, Los Angeles, appears to have settled whatever ambiguity remains . "It's in the nucleus," said Wilson. "All the antibodies that are specific show distinctive nuclear dot patterns in cells." She compared 20 antibodies from several groups using many testswestern blotting, immunoprecipitation, immunohistochemistry, and cytochemistry on individual cells. Because BRCAI protein is expressed at very low levels in the nucleus, very clean antibodies are required to see it.
Besides cellular location, another clue to function comes from discovering the proteins that interact with BRCA I. To date, the list has grown quite large, including several enzymes (e.g., helicase, RNA polymerase, and ubiquitin hydrolase) as well as other proteins (e.g., Rad51 , p53, BARDI , and CTIP). So far, no clear consensus has emerged about which protein s are important to BRCA I 's function.
Adding to the murky picture, is the inability of researchers to produce mice lacking two copies offunctional BRCAI genes, so-called knock-out mice, which frequentl y provide insights into the function of the missing gene. Mouse embryos lacking BRCAI protein do not survive.
Given these problems, a paper in the Aug. 14 Scien ce was a first -the first direct function al evidence for BRCA I. Researchers from the Department of Radiation Oncology, University of North Carolina at Chapel Hill, showed that cells deficient in BRCAI were unable to repair DNA that was damaged by either ionizin g radiation (gamma radiation ) or hydrogen peroxide. The particular kind of repair that is defecti ve in these cells is called transcript ion-coupled repair (TCR) -involving machinery that tags along with RNA polymera se and repairs actively transcribing genes.
"Our results make sense with the data that show an association between BRCAI and RNA polymerase," said Lori Gowen, a UNC graduate student and the paper's first author. "And it is consistent with BRCAI being a tumor suppre ssor gene -mutations will accumulate if the gene is involved in repair. But it still doesn't allow us to say whether BRCAI is a part of the repair machine ry or a transcription factor that regulates transcription of genes involved in TCR."
And that seems to be precisely the problem -developing a good system for analyzing BRCAI , either in mice or in human cancer cells. The gene's enormous size suggests that the BRCAI protein is likely to have several functions, probably involving DNA repair, transcriptional regulation of genes, or others.
Ralph Scully, M.D., Ph.D., a researcher in David Livingston's lab at the Dana-Farber Cancer Institute , Harvard Medical School, Boston, who discovered that BRCA I associates with Rad51 , believes the only way to make progress is to develop a good genetic system. "We need a tractable genetic system to test out key hypotheses in the field. For example, we need to be able to add back normal BRCAI to cells lacking functional BRCAI and show that a specific defect can be reversed," he said.
Chodosh has published a series of articles during the last three years looking at the pattern of expression of both genes during embryogenesis, in a variety of adult tissues, and in mammary glands during different developmental stages.
"Basically you can't tell them apart," remarked Chodosh. "It's remarkable. We looked at over 20 tissues, and what's extraordinary is not just that BRCAI and BRCA2 are expressed in the same tissues, but that they're expressed at the same relative levels within the same cellular compartments and at the same developmental stages within those tissues. Youjust don't find that for very many genes in nature."
Because of these data, he believes that BRCAI and BRCA2 are likely to be interconnected. His sense is that within the nucleus are dynamic macromolecular complexes that include BRCA1I2, Rad51, and other DNA damage-related proteins.
"My guess is that there are probably three, four, five or more proteins in these complexes. The particular proteins present or absent will be different, depending on the state of the cell and the state of DNA damage," he speculated.
Ralph Scully, M.D., Ph.D., a researcher in David Livingston's lab at the Dana-Farber Cancer Institute at the Harvard Medical School, agrees that BRCA1I2 functions are probably intertwined. In support of this, the Livingston group has recently shown in a paper published in September in Molecular Cell that BRCAI and BRCA2 interact biochemically, although it is not yet clear whether this interaction is direct or indirect.
One hypothesis advanced by the group is that both genes are involved in maintaining the integrity of the DNA into breast tissue, which is uniquely 
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vulnerable to assaults from carcinogens throughout life -during menarche, breast development, and pregnancy. One candidate is a metabolite of estrogen.
For the moment, however, until a consensus emerges, the data linking BRCA2 's function to the repair of DNA breaks offers the most promise for translating knowledge offunction into effective rational therapy. If progress in the BRCA2 field continues at its present pace, the answers from the clinic should be in relatively soon.
-NancyJ. Nelson
NSABP Names Centers For Study of Tamoxifen And Raloxifene (STAR)
The National Surgical Adjuvant Breast and Bowel Project has selected 193 institutions to participate in its second major breast cancer prevention trial, the Study of Tamoxifen and Raloxifene. The new study, which is expected to begin early next year, will randomize 22,000 postmenopausal women at high risk for breast cancer to receive either raloxifene or tamoxifen.
STAR will examine whether raloxifene, a drug similar to tamoxifen, is also effective in preventing invasive breast cancer in women who have not had the disease and whether it offers any benefits over those oftamoxifen. Participants in the STAR study, who must be 35 years of age or older, will be followed closely through mammograms, physical exams, and gynecologic exams on a regular basis for at least 7 years.
More information is available at www.nsabp.pitt.edu. Even without much clinical evidence, the 300 tea-swilling scientists and industry representatives who gathered at the Second International Symposium on Tea & Human Health, held in Washington in September, were steeped in news from a dozen promising studies.
Most of this research focused on the basic chemistry and biology of catechins. Among the results: Tea contains more antioxidants than do most fruits and vegetables; downing a single cup of
